HQL
$12.64
Revenue | $2.18Mn |
Tekla Life Sciences Investor’s revenue jumped 93.47% since last year same period to $2.18Mn in the Q1 2020. On a quarterly growth basis, Tekla Life Sciences Investor has generated 65.87% jump in its revenue since last 3-months.
EPS Estimate Current Year | 0 |
Tekla Life Sciences Investor’s earning per share (EPS) estimates for the current year stand at 0.
Return on Assets (ROA) | -0 |
Return on Equity (ROE) | 0.01 |
Dividend Per Share (DPS) | 0.33 |
Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Tekla Life Sciences Investor’s return on assets (ROA) stands at -0.
The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Tekla Life Sciences Investor’s return on equity (ROE) stands at 0.01.
Tekla Life Sciences Investor declared 0.33 dividend per share during the earnings announcement for Q1 2023.
Earnings Date | Estimated EPS | Reported EPS | Surprise % |
---|---|---|---|
2020-03-31 | 0 | 1.29 | +Inf% |